New studies aim to improve treatments for advanced breast cancer

Photo credit: National Institutes of Health 

Advancements in treatment and early detection have improved survival for women diagnosed with breast cancer. For patients with locally advanced or metastatic breast cancer, better therapies are needed. Two new studies at Providence Cancer Institute seek to improve treatment options for patients with advanced breast cancer:

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04)

The HER2CLIMB-04 phase II, single-arm study will evaluate the effectiveness of tucatinib (Tukysa) when given with trastuzumab deruxtecan (Enhertu) in patients with metastatic or unresectable HER2-positive breast cancer whose disease progressed on prior therapies.

Tucatinib is a HER2 inhibitor and transtuzumab deruxtecan and is an antibody-drug conjugate. Both therapies are approved for HER2-positive breast cancer after prior studies found clinical benefit.

A Study Evaluating the Efficacy and Safety of GDC-0077 plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer

This phase III, randomized, double-blind study tests the effectiveness of GDC-0077, an experimental PI3K inhibitor, compared to placebo in patients with HER2-negative locally advanced or metastatic breast cancer that contains hormone receptors and the PIK3CA gene mutation.

Both GDC-007 and placebo will be given in combination with standard of care palbociclib (Ibrance) and fulvestrant (Falsodex).

Medical oncologist Alison Conlin, M.D., MPH, oversees a vast portfolio of cancer clinical trials and serves as principal investigator of these studies.

For more information or to enroll a patient, call our Clinical Research office at 503-215-2614, send an email or submit a referral form.

See more breast cancer studies

More than 20 research studies investigating a broad spectrum of breast cancer therapies and interventions are open at Providence Cancer Institute. We offer studies aimed at improving cure rates, quality of life and survival for both early-stage and metastatic breast cancer patients. These studies range from our own investigator-initiated research studies to large international studies, including studies from the National Cancer Institute and from pharmaceutical industry partners.

New studies are added frequently. Please visit our website to view all breast cancer studies or view our complete list of studies for all cancers at Providence Cancer Institute.

A team of breast cancer specialists

The research team at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute at the Robert W. Franz Cancer Center, includes oncologists who specialize exclusively in breast cancer, as well as breast-cancer-focused laboratory scientists, research nurses, data coordinators and lab assistants. Every person on this team is passionate about providing the highest quality of care and the most promising treatments for patients with breast cancer. To learn more about our comprehensive care for patients with breast cancer, visit Providence Breast Services.

Previous Article
Nuance and Providence collaborate to create a better patient experience and ease clinician burden
Nuance and Providence collaborate to create a better patient experience and ease clinician burden

The strategic collaboration will focus on AI-powered solutions to assist with clinician-patient documentati...

Next Article
Providence researchers featured at cancer immunotherapy conference
Providence researchers featured at cancer immunotherapy conference

Investigators present latest research in cancer immunotherapy, receive noteworthy awards, at the 35th annua...